J2351 Injection ocrelizumab 1mg hya-ocsq
Also known as: ocrelizumab, Hyalogic OCSQ ocrelizumab
Injection of ocrelizumab 1 mg (Hyalogic OCSQ brand). A CD20-targeted monoclonal antibody from specific manufacturer.
In Plain Language
MS treatment; B cell antibody
Clinical Context
Identical clinical use to standard ocrelizumab for multiple sclerosis. Hyalogic OCSQ is a specific manufacturer formulation.
RVU Information
CPT J2351 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2351?
CPT J2351 (Injection ocrelizumab 1mg hya-ocsq) is a J Codes (Drugs) code. Injection of ocrelizumab 1 mg (Hyalogic OCSQ brand). A CD20-targeted monoclonal antibody from specific manufacturer.
How is J2351 administered?
CPT J2351 is administered by a healthcare provider, typically via injection or infusion. Identical clinical use to standard ocrelizumab for multiple sclerosis. Hyalogic OCSQ is a specific manufacturer formulation. It is used by Neurology, Immunology.
When is CPT J2351 used?
Identical clinical use to standard ocrelizumab for multiple sclerosis. Hyalogic OCSQ is a specific manufacturer formulation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.